Intense metabolic control decreases long-term mortality and morbidity in diabetics with myocardial infarction  by Malmberg, K. & Rydén, L.
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aPTT at 12 Hours (SEC) 
tool when the target level of anticoagulation is set below 85 seconds - -  a 
common range in current practice, 
[ '~ -3 - '~  Intense Metabolic Control Decreases Long-Term 
Mortal ity and Morbidity in Diabetics With 
Myocardial  Infarction 
K. Malmberg, L Ryd~n, for t~e Swedish DIGAMI Study Group. Cardiology 
Department, Karolinska Hospital, Stockholm, Sweden 
Diabetic pat with acute myocardial infarction (AMI) has a poor prognosis. 
Recent data indicate that glycemic control predicts cardiovascular morbidity 
and mortality in non insulin dependent. 
Material and methods: We tested insulin-glucose infusion as soon as 
possible after onset of AMI followed by ibng-term multi dose insulin in a 
prospective rendemlsed study (DIGAMI) recruiting 620 diabetic pat with AML 
Half of the pat served as a control group (CG) while the remaining subjects 
constituted an insulin treatred group (IG). Data are from one year of follow 
up. 
Results: One year mortality decreased from 26=/0 in the CG to 19=/o in the 
IG (p < 0.05). The effect was most pronounced in diabetics without previous 
insulin and at low cardiovascular isk (reduction = 52%; < 0.02). The most 
frequent cause of mortality was congestive heart failure (CHF), Cardiovas- 
cular mortality (CHF, fatal rainfamtion, sudden death, stroke) tended to be 
less frequent in the IG. The two groups did differ as regards need for revas- 
cularication or hospital care during the year of follow up. Rainfarction was 53 
(28% fatal) in the IG vs 55 (45% fatal) in CG (NS). In a multivariate analysis 
age, previous CHF, admission blood glucose and previous insulin therapy 
independently predicted one year mortality. Metabolic control at admission 
predicted mortality in CG but not in IG. Concomitant beta blockade was a 
predictor for survival among CG whereas thmmbolysfs was most efficient in 
IG. 
Conclusion: Fatal reinfarction and CHF contribute to the increased mortality 
in diabetic pat with AMI. Intensive metabolic ontrol by means of insulin lowers 
mortality and morbidity. Beta blockade did not exert further benefits in Insulin 
treated pat indicating similar mechanisms of action. 
~ Effect Lisinopri l  on Early Mortality o f  Treatment in 
Patients With Acute Myocardial InfareUon at 
Different Risk Profile: Data From the GISSI-3 Study 
GISSI-3 Investigators. M. I~egri Insfitute and ANMCO, Italy 
GISSI-3, ISIS-4, and CCS-1 trials showed a mortality reduction with an early 
(within 24-36 h) treatment with ACE-inhibitors (ACE-i) of unsaiectad 10ts with 
AML In these trials a significant reduction in mortality was already evident in 
the first 5 days of treatment. In pts enrolled in the GISSI-3 study, we evaluated 
early (0 to 5 days) mortality in lisinopdl (L) and no-lisinopril (no-L) treated pts, 
split by subgroups at different baseline risk. 
0-5 days mortality % L no.L  Reduction Livestsaved 
% x 1000 
Overall (n.19318) 3.3 3,8 -13.1 5 
Killip 1 (n.18035) 2.5 2.9 -13.8 4 
Killip 2 + 3 (n.2738) 8.3 9.5 -12.6 12 
Anterior MI (n.5188) 2.5 3.4 -26.5 9 
Inferior MI (n.6105) 1.1 1.6 -31.2 5 
The trend in early mortality reduction was consistent in all subgroups at 
different risk profile, with a greater absolute benefit in the subgreuns at higher 
risk. Analyzing the time course of the L effect split by Killip class at entry, 
an early benefit from L treatment was observed either in patients in Killip 
class 1 or in those in Killip class 2 or 3. From day 6 to 42, no further benefit 
could be seen in lots in Killip class f, while Killip class 2 or 3 pts showed, 
as expected, a further late mortality reduction (18 lives saved per 1000), 
being these patients similar to those randomized in the AIR; study. These 
findings support an early treatment with ACE-i of relatively unselected pts 
with MI and its continuation for a long period of time only in those with 
post-AMI left ventricular failure and/or dysfunction. Further investigations 
are needed to explain the mechanisms underlying the early benefit, which 
appears different from and complementary to the favourabte modifications of 
ventrlcular emodelling induced by ACE-L 
Effects on Venlr icular Arrhythmlas of  an Early 
Uainopdl  Treatment In Patients With Acute 
Myocardial Infarction: The GISSI-3 Experience 
Aldo P. Maggioni, Fabrlzio Pizzetti, Eugenio Santoro, Roberto Latini, 
Giulio Zuanetti, MarlaGrazia Frenzosi, on behalf of the GISSI.3 
Investigators. ANMCO and M. Negri Institute, Italy 
The activation of renin-angiotensin-aldosterone system after myocardial in- 
farction (MI) can increase frequency and complexity of ventrlcular arrbyth- 
mias (VA) after MI. The effects of a lisinopdl (L) treatmenL started in GISSI-3 
study within 24 h from symptom onset, was evaluated on (a) life-threatening 
VA in the 18895 pts with complete in-hospital data and (b) VA profile in the 
12"327 pts with pre~ischarge 24 h ECG monitoring data available. 
The rate of pts with In-hospital life-threatening VA and with VA at predis- 
charge 24 hour ECG monitoring in the L and no.L groups is reported In the 
table: 
In-Hospital VA Lisinopdl (n.9435) No-Ustnopril (n.9460) 21) 
VF % 2.5 2.7 NS 
sVT % 1.9 2.4 0.03 
VF and/or sv'r % 4.0 4.7 0.01 
24 h ECG VA Lisinopril (n.6165) No-Usinopril (n.6162) 2p 
0 PVC % 39.1 39.0 NS 
1-10 PVCs % 43.1 42.8 NS 
> 10 PVCs/h % 17.8 18.2 NS 
nsVT % 5.2 5.1 NS 
VF = ventficular fibrillation, SVT = sustained ventficular tachicardia, PVC = premature ven- 
tricular contractions, nsVT = non-suslained ventricular laehlcardia. 
While L treatment did not influence the VA profile detected by pre<lischarge 
24 h ECG monitoring, in-hospital life-thraatening VA ware less frequent in pts 
allocated to L, This "antiarrbythmib" effect of L in the early phase of MI could 
have contributed to the reduction of eady mortality shown with this treatment 
in GISSI-3 trial. 
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~ " ~  Analysis of the Occurrence and Clinical 
Significance of  Thrombocytopenla  With c7E3 
(Abciximab) in the EPIC Trial 
scott D. Berkowitz, David C. Sane, Jane H. Shavender, Kristina N. Sigmon. 
Eric J. Topoi, Robert M. Ca,if, for the Evaluation of 7E3 for the Prevention of 
Ischemic Complications (EPIC) Study Group. Duke University; Durham, NC; 
Wake Forest University, Winston-Salem, NC 
To understand the role of thrombocyfopenia (7) in hemorrhagic omplica- 
tions associated with the plataiet GP lib/Ilia inhibitor c7E3 (abciximab), we 
analyzod the data from EPIC, a 2,099 patient randomized trial of placebo (P), 
c7E3 bolus (B), or c7E3 bolus + 12 hr infusion (B +/) during PTCA. Twas 
defined as a platelet decrease to < 100 K/pl. Nadir platslet counts did not 
differ between those receiving c7E3 or P (mean 67.7 vs 68.6). Twas more 
likely to occur in patients who were older (mean 64 vs 60 yr), had peripheral 
vascular disease (15 vs 9%) and 3 vessel coronary disease (26 vs 14%). 
Twas associated with recurrent ischemia, more frequent revascoladzation, 
and increased mortality. A trend toward excess Twas seen in the B + I (5.4%) 
versus the B (3.0=/°) and P (3.3%) groups. Patients receiving c7E3 B+ /more 
frequently developed severe T [< 50 Wpl] (1.6%; B 0.4%, P 0.7%). In a 
logistic regression model, the B + I group had a significant relationship with 
T (p = 0.016), which became more significant after adjustment for CABG, 
repeat PTCA, and IABP insertion (p = 0.014). Those with Thad more groin 
site (68 vs 39°/°) and GU tract (10 vs 4=/o) bleeding and hematemeais (10 vs 
0%), but no intracranial hemorrhages or thromboses. In conclusion, we found 
a small but increased likelihood of developing Tin patients receiving c7E3, 
particularly a + I, Among all patients, c7E3 was associated with reduced 
ischemib complications; however, those who developed Twere at increased 
risk of developing iechemia-associated morbidity and mortality. 
